Viral Vector Production (Research-Use) Market: AAV Segment Dominated And Accounted For The Largest Revenue Share
Viral Vector Production (Research-use) Industry Overview
The global viral vector production (research-use) market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The expanding research base for advanced therapies has primarily driven the market for research applications including preclinical, clinical, and investigational studies.
The outbreak of the COVID-19 pandemic has created lucrative opportunities for the market players, particularly in the vaccine manufacturing sector. The application of viral vectors in vaccine development against SARS-CoV-2 has witnessed remarkable growth in the fiscal year 2020. By far, the manufacturing of viral vectors for research use is impeded by a lack of production capacity to fulfill the growing market needs.
Thus, operating key stakeholders are engaged in implementing new approaches to overcome these challenges and expand production capacities. The improving ratio of clinical success to the number of clinical trials of gene and cell therapy products is a testament to the enhancing manufacturing capabilities.
Currently, several new gene therapy products are in the late stages of development and the pipeline continues to expand across the globe. The forward momentum for the advanced therapy arena is anticipated to drive investment to conduct research for the development of safe viral vectors and therapies.
Viral Vector Production (Research-use) Market Segmentation
Grand View Research has segmented the global viral vector production (research-use) market on the basis of vector type, application, workflow, end-use, and region:
Based on the Type Insights, the market is segmented into Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, and Others.
- In 2020, the AAV segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 22.0%. The adenovirus segment accounted for a significant revenue share in 2020 owing to the increased employment in COVID-19 vaccine
- Lentiviral vectors have witnessed huge success in reprogramming induced Pluripotent Stem Cells (iPSC). This has created opportunities for therapeutic research using iPSC technology. Researchers are also deciphering the potential of Non-integrating lentiviral vectors (NILVs) as a tool to avoid insertional mutagenesis, resulting in the fastest growth of this segment.
Based on the Application Insights, the market is segmented into Cell & Gene Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, and Biomedical Research.
- Viral vectors have been thoroughly studied in various animal models and several viruses have been explored as vaccine vectors eventually entering clinical development. Adenovirus and vaccinia virus are some of the most commonly used viral vectors for vaccine development, owing to their high potential for inducing a strong immune response against a foreign body.
- The cell and gene therapy development segment is gaining momentum over the past few years. With high investment flow, the R&D activities in this space are rapidly increasing, consequently leading to market growth. As per an article published in June 2020, 70% of clinical trials conducted for gene therapy have utilized viral vectors.
Based on the Workflow Insights, the market is segmented into Upstream Processing, and Downstream Processing.
- The downstream processing segment held a significant share in 2020 owing to the highly complex procedures administered to generate polished and purified clinical-grade final products. Also, the high cost associated with purification techniques has led to the high revenue generation in this segment.
- Upstream processing involves vector amplification, expansion, and harvesting. The companies such as Sartorius AG offer advanced products like the ambr 15 micro bioreactor system, which is anticipated to accelerate the market growth. Moreover, the easy availability of single-use equipment for upstream processing that in turn offer several monetary benefits would spur the growth in this space.
Based on the End-use Insights, the market is segmented into Pharmaceutical and Biopharmaceutical Companies, and Research Institutes.
- The research institutes segment dominated the market for viral vector production (research-use) and accounted for the largest revenue share of 57.0% in 2020. This can be attributed to the high involvement of the global research community in the development of advanced therapies for the treatment of several genetic and acquired diseases that previously lacked an effective treatment paradigm.
- The outbreak of the COVID-19 infection has encouraged the research community to shift their focus on the development of a vaccine against the disease in urgency. This increased the demand for viral vectors by the research institutes. Apart from COVID-19, the researchers are engaged in R&D in vaccinology for diseases such as HIV and Hepatitis B, thus leading to significant revenue growth.
Viral Vector Production (Research-use) Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies & Market Share Insights
The increasing number of companies involved in gene and cell therapy development as well as the development of vaccines is anticipated to intensify the market competition in this space. Besides, contract research organizations are also supplementing the revenue generation by a robust increase in service demand.
Owing to the rapidly increasing demand for viral vectors in research settings, several strategic initiatives are being undertaken by the operating entities to enhance their market presence. Capacity expansion is the major initiative taken by the companies. For instance, in January 2021, FUJIFILM Corporation invested USD 40 million to advance viral vector manufacturing capabilities. Some of the prominent players in the viral vector production (research-use) market include:
- Merck KGaA
- Lonza
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Cobra Biologics Ltd.
- Thermo Fisher Scientific
- Waisman Biomanufacturing
- Genezen
- YPOSKESI
- Advanced BioScience Laboratories, Inc. (ABL, Inc.)
- Novasep Holding S.A.S
- Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
- Vigene Biosciences, Inc.
- General Electric Company (GE Healthcare)
- CEVEC Pharmaceuticals GmbH
- Batavia Biosciences B.V.
- Biovion oy
- Wuxi AppTec Co., Ltd.
- VGXI, Inc.
- Catalent Inc.
- Miltenyi Biotec GmbH
- SIRION Biotech GmbH
- Virovek Incorporation
- BioNTech IMFS GmbH
- VIVEbiotech S.L.
- Creative Biogene
- Vibalogics GmbH
- Takara Bio.
- Cell and Gene Therapy Catapult
- BlueBird Bio
- Addgene, Inc.
- Aldevron, L.L.C.
- Audentes Therapeutics
- BioMarin Pharmaceutical
- RegenxBio, Inc.
Order a free sample PDF of the Viral Vector Production (Research-use) Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Comments
Post a Comment